Medullary thyroid cancer (MTC) represents an aggressive form of thyroid malignancy. Some
may occur spontaneously or can be associated with Multiple Endocrine Neoplasia …

SUMMARY The US Food and Drug Administration (FDA) approved vandetanib in April 2011
for the treatment of unresectable, locally advanced or metastatic medullary thyroid cancer …

Medullary thyroid cancer (MTC) is frequently diagnosed in a locally advanced or metastatic
stage, and 10-year survival rates in these cases are below 20%. Cytotoxic chemotherapy …

Traditionally available treatments, like cytotoxic chemotherapy and external-beam radiation
therapy, are limited and essentially ineffective for metastatic medullary thyroid carcinoma …

Vandetanib (ZD6474) became the first systemic agent to be approved for the treatment of
metastatic or locally advanced medullary thyroid cancer. It was a proof of principle, because …

Objective: To review the place in therapy of vandetanib for medullary thyroid carcinoma
(MTC). Data Sources: Literature searches were performed in Ovid MEDLINE, EMBASE, and …

Abstract On April 6, 2011, the US Food and Drug Administration approved vandetanib
(Caprelsa tablets; AstraZeneca Pharmaceuticals LP) for the treatment of symptomatic or …

Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of
multiple growth factor receptors, including RET (Rearrange during transfection), vascular …

Introduction: The tyrosine kinase inhibitor vandetanib was approved for use in 2012 for
aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable …

Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …